PAS-004 Tablets Show Promise for NF1 Plexiform Neurofibromas PAS-004 tablets show dose-proportional, predictable pharmacokinetics with less variability than capsules, supporting improved dosing for NF1-PN.

#PAS004 showed a long half-life of approximately 57 hours, supporting their potential for improved patient dosing and therapeutic consistency in #NeurofibromatosisType1 (NF1)-associated plexiform #Neurofibromas, Pasithea Therapeutics announced.

Read here: https://bit.ly/3KmA4z3

#RareDisease #NF1

Auction Bid There are countless ways to fundraise or collect donation...

2nd Annual NF HOPE Concert! C'Mon! Great cause, Great auction. @jeffleibow #neurofibromas #patients #hcsm http://nfhope.auction-bid.org/